TCRX logo

TScan Therapeutics (TCRX) Company Overview

Profile

Full Name:

TScan Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 16, 2021

Indexes:

Not included

Description:

TScan Therapeutics (TCRX) is a biotechnology company focused on developing innovative T cell receptor (TCR) therapies for cancer treatment. They aim to harness the body’s immune system to target and eliminate cancer cells, offering potential new options for patients with various types of tumors.

Key Details

Price

$2.25

Annual Revenue

$21.05 M(+55.52% YoY)

Annual EPS

-$1.36(+50.55% YoY)

Annual ROE

-71.29%

Beta

1.31

Events Calendar

Earnings

Next earnings date:

Mar 6, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 6, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 11, 24 Needham
Buy
Dec 11, 24 HC Wainwright & Co.
Buy
Nov 15, 24 HC Wainwright & Co.
Buy
Nov 12, 24 Needham
Buy
Nov 6, 24 Needham
Buy
Aug 13, 24 Wedbush
Outperform
Aug 13, 24 HC Wainwright & Co.
Buy
Aug 12, 24 Needham
Buy
Jun 4, 24 HC Wainwright & Co.
Buy
May 16, 24 BTIG
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
TCRX
zacks.comJanuary 10, 2025

The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
TCRX
globenewswire.comDecember 26, 2024

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an aggregate of 7,500,000 shares of its voting common stock at a price of $4.00 per pre-funded warrant, each exercisable to purchase one share of voting common stock at an exercise price of $0.0001 per share, representing a premium of 37% to the last closing price of TScan Therapeutics' common stock, and a 34% premium over the 10-day volume weighted average closing price. The financing is expected to close on or about December 27, 2024, subject to customary closing conditions.

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
TCRX
globenewswire.comDecember 23, 2024

New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
TCRX
globenewswire.comDecember 9, 2024

To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14)

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
TCRX
globenewswire.comDecember 5, 2024

WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) --  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced it has been named one of the Top Places to Work in Massachusetts in the 17th annual, employee-based survey from The Boston Globe. The 2024 Top Places to Work issue was published online at Globe.com/TopPlaces and will appear in Globe Magazine on Sunday, December 8, 2024.

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
TCRX
zacks.comNovember 12, 2024

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per share a year ago.

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
TCRX
zacks.comNovember 7, 2024

TScan Therapeutics (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
TCRX
globenewswire.comNovember 5, 2024

All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, at 8:00 a.m.

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TCRX
globenewswire.comOctober 4, 2024

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually.

TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics to Participate in Upcoming Investor Conferences
TCRX
globenewswire.comAugust 29, 2024

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for TScan Therapeutics?
  • Does TScan Therapeutics pay dividends?
  • What sector is TScan Therapeutics in?
  • What industry is TScan Therapeutics in?
  • What country is TScan Therapeutics based in?
  • When did TScan Therapeutics go public?
  • Is TScan Therapeutics in the S&P 500?
  • Is TScan Therapeutics in the NASDAQ 100?
  • Is TScan Therapeutics in the Dow Jones?
  • When was TScan Therapeutics's last earnings report?
  • When does TScan Therapeutics report earnings?
  • Should I buy TScan Therapeutics stock now?

What is the ticker symbol for TScan Therapeutics?

The ticker symbol for TScan Therapeutics is NASDAQ:TCRX

Does TScan Therapeutics pay dividends?

No, TScan Therapeutics does not pay dividends

What sector is TScan Therapeutics in?

TScan Therapeutics is in the Healthcare sector

What industry is TScan Therapeutics in?

TScan Therapeutics is in the Biotechnology industry

What country is TScan Therapeutics based in?

TScan Therapeutics is headquartered in United States

When did TScan Therapeutics go public?

TScan Therapeutics's initial public offering (IPO) was on July 16, 2021

Is TScan Therapeutics in the S&P 500?

No, TScan Therapeutics is not included in the S&P 500 index

Is TScan Therapeutics in the NASDAQ 100?

No, TScan Therapeutics is not included in the NASDAQ 100 index

Is TScan Therapeutics in the Dow Jones?

No, TScan Therapeutics is not included in the Dow Jones index

When was TScan Therapeutics's last earnings report?

TScan Therapeutics's most recent earnings report was on Nov 12, 2024

When does TScan Therapeutics report earnings?

The next expected earnings date for TScan Therapeutics is Mar 6, 2025

Should I buy TScan Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions